ondansetron has been researched along with Depression in 18 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the effect of ondansetron on symptoms of patients with subjective tinnitus accompanied by sensorineural hearing loss or normal hearing." | 9.17 | Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study. ( Fallah, AY; Hosseini, M; Modabbernia, A; Pourvaziri, A; Taslimi, N; Taslimi, S; Vahidi, H; Yazdani, N; Zarandi, MM, 2013) |
| "The 5-hydroxytryptamine receptor type 3 antagonist ondansetron had a significant positive effect on fatigue in CHC." | 9.11 | Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. ( Antoun, Z; Benzaken, S; Caroli-Bosc, FX; Cherikh, F; Demarquay, JF; Gelsi, E; Huet, PM; Piche, T; Rampal, P; Renou, C; Rigault, MC; Tran, A; Vanbiervliet, G, 2005) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 7.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| "The aim of the present work was to investigate the role of ondansetron on the high fat diet (HFD) induced obese mice for behavioral and biochemical alterations using chronic unpredictable mild stress (CUMS) model of depression." | 7.80 | Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 7.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| "The aim of this study was to assess the effect of ondansetron on symptoms of patients with subjective tinnitus accompanied by sensorineural hearing loss or normal hearing." | 5.17 | Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study. ( Fallah, AY; Hosseini, M; Modabbernia, A; Pourvaziri, A; Taslimi, N; Taslimi, S; Vahidi, H; Yazdani, N; Zarandi, MM, 2013) |
| "The 5-hydroxytryptamine receptor type 3 antagonist ondansetron had a significant positive effect on fatigue in CHC." | 5.11 | Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. ( Antoun, Z; Benzaken, S; Caroli-Bosc, FX; Cherikh, F; Demarquay, JF; Gelsi, E; Huet, PM; Piche, T; Rampal, P; Renou, C; Rigault, MC; Tran, A; Vanbiervliet, G, 2005) |
| " In the prelevodopa era, depression and other psychiatric disorders were described in PD, but in untreated patients psychosis was rare." | 4.79 | Parkinson's disease: drug-induced psychiatric states. ( Brown, D; Factor, SA; Molho, ES; Podskalny, GD, 1995) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 3.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| "The aim of the present work was to investigate the role of ondansetron on the high fat diet (HFD) induced obese mice for behavioral and biochemical alterations using chronic unpredictable mild stress (CUMS) model of depression." | 3.80 | Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 3.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| "We describe a patient with chronic depression who was treated with the selective serotonin-reuptake-inhibitor sertraline." | 3.69 | [The clinicopharmacological case (5). serotonin reuptake inhibitor and 5-HT3-receptor antagonists: are there clinically relevant interactions?]. ( Fattinger, K; Kind, B; Krähenbühl, S; Meier-Abt, PJ, 1996) |
| "The effects of the 5-HT3 receptor antagonists, zacopride, ondansetron and ICS 205-930, were investigated in an animal model of depression, the learned helplessness test." | 3.68 | 5-HT3 receptor antagonists reverse helpless behaviour in rats. ( Gozlan, H; Martin, P; Puech, AJ, 1992) |
| "Double-blind treatment of severe bulimia nervosa subjects with ONDAN resulted in a rapid and significant decrease in binge-eating and vomiting compared to placebo controls." | 2.43 | Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. ( Eckert, ED; Faris, PL; Goodale, RL; Hartman, BK; Kim, SW; Meller, WH; Pardo, JV, 2006) |
| "Both paroxetine and pargyline were effective in reducing the immobility time of stressed OVX mice in the FST." | 1.38 | Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system. ( Bazanella Sampaio, T; Mozzaquatro Gai, B; Nogueira, CW; Pinton, S; Trevisan da Rocha, J; Zeni, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahesh, R | 3 |
| Devadoss, T | 2 |
| Pandey, DK | 2 |
| Bhatt, S | 2 |
| Yadav, SK | 1 |
| Wang, W | 1 |
| Lou, G | 1 |
| Zhang, Y | 1 |
| Gupta, D | 3 |
| Radhakrishnan, M | 3 |
| Kurhe, Y | 4 |
| Bétry, C | 1 |
| Overstreet, D | 1 |
| Haddjeri, N | 1 |
| Pehrson, AL | 1 |
| Bundgaard, C | 1 |
| Sanchez, C | 1 |
| Mørk, A | 1 |
| Shimizu, K | 1 |
| Kurosawa, N | 1 |
| Seki, K | 1 |
| Sumaya, IC | 1 |
| Bailey, D | 1 |
| Catlett, SL | 1 |
| Verwimp-Hoeks, MPA | 1 |
| van Herpen, CML | 1 |
| Burger, DM | 1 |
| Trevisan da Rocha, J | 1 |
| Mozzaquatro Gai, B | 1 |
| Pinton, S | 1 |
| Bazanella Sampaio, T | 1 |
| Nogueira, CW | 1 |
| Zeni, G | 1 |
| Taslimi, S | 1 |
| Vahidi, H | 1 |
| Pourvaziri, A | 1 |
| Modabbernia, A | 1 |
| Fallah, AY | 1 |
| Yazdani, N | 1 |
| Taslimi, N | 1 |
| Hosseini, M | 1 |
| Zarandi, MM | 1 |
| Kumar, B | 1 |
| Jindal, A | 1 |
| Piche, T | 1 |
| Vanbiervliet, G | 1 |
| Cherikh, F | 1 |
| Antoun, Z | 1 |
| Huet, PM | 1 |
| Gelsi, E | 1 |
| Demarquay, JF | 1 |
| Caroli-Bosc, FX | 1 |
| Benzaken, S | 1 |
| Rigault, MC | 1 |
| Renou, C | 1 |
| Rampal, P | 1 |
| Tran, A | 1 |
| Faris, PL | 1 |
| Eckert, ED | 1 |
| Kim, SW | 1 |
| Meller, WH | 1 |
| Pardo, JV | 1 |
| Goodale, RL | 1 |
| Hartman, BK | 1 |
| Factor, SA | 1 |
| Molho, ES | 1 |
| Podskalny, GD | 1 |
| Brown, D | 1 |
| Kind, B | 1 |
| Fattinger, K | 1 |
| Krähenbühl, S | 1 |
| Meier-Abt, PJ | 1 |
| Martin, P | 1 |
| Gozlan, H | 1 |
| Puech, AJ | 1 |
2 reviews available for ondansetron and Depression
| Article | Year |
|---|---|
Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms.
Topics: Bulimia Nervosa; Depression; Humans; Neurons, Afferent; Ondansetron; Pain; Pain Measurement; Seroton | 2006 |
Parkinson's disease: drug-induced psychiatric states.
Topics: Aged; Anxiety; Bipolar Disorder; Clozapine; Depression; Electroconvulsive Therapy; Humans; Levodopa; | 1995 |
2 trials available for ondansetron and Depression
| Article | Year |
|---|---|
Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study.
Topics: Adult; Aged; Anxiety; Depression; Double-Blind Method; Female; Hearing Loss, Sensorineural; Humans; | 2013 |
Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Depression; Double-Blind Method; Fatigue; Female; Hep | 2005 |
14 other studies available for ondansetron and Depression
| Article | Year |
|---|---|
Design, synthesis and structure-activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression.
Topics: Amides; Animals; Depression; Drug Design; Guinea Pigs; Mice; Quinoxalines; Receptors, Serotonin, 5-H | 2010 |
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Anxiety; Benzodiazepines; Cisplatin; Depression; De | 2018 |
5HT3 receptor antagonist (ondansetron) reverses depressive behavior evoked by chronic unpredictable stress in mice: modulation of hypothalamic-pituitary-adrenocortical and brain serotonergic system.
Topics: Adrenal Cortex; Animals; Behavior, Animal; Brain; Corticosterone; Depression; Hypothalamo-Hypophysea | 2014 |
Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Brain; Depression; Depressive Disor | 2014 |
Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Topics: Animals; Antidepressive Agents; Antiemetics; Anxiety; Behavior, Animal; Brain; Depression; Depressiv | 2014 |
A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant.
Topics: Animals; Depression; Disease Models, Animal; Dorsal Raphe Nucleus; Drug Synergism; Electrophysiologi | 2015 |
Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Topics: Animals; Anxiety; Behavior, Animal; Body Weight; Brain; Citalopram; Corticosterone; Depression; Diet | 2015 |
The role of the AMPA receptor and 5-HT(3) receptor on aggressive behavior and depressive-like symptoms in chronic social isolation-reared mice.
Topics: Aggression; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amygdala; Animals; Depression; | 2016 |
Differential effects of a short-term high-fat diet in an animal model of depression in rats treated with the 5-HT3 receptor antagonist, ondansetron, the 5-HT3 receptor agonist, 2-methyl-5-HT, and the SSRI, fluoxetine.
Topics: Animals; Depression; Diet, High-Fat; Disease Models, Animal; Fluoxetine; Male; Ondansetron; Rats; Ra | 2016 |
Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer.
Topics: Adult; Antidepressive Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Carcinoma; Chemoradiot | 2012 |
Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system.
Topics: Animals; Antidepressive Agents; Benzene Derivatives; Cerebral Cortex; Depression; Disease Models, An | 2012 |
Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Emotions; Mice; Olfactory Bul | 2012 |
[The clinicopharmacological case (5). serotonin reuptake inhibitor and 5-HT3-receptor antagonists: are there clinically relevant interactions?].
Topics: 1-Naphthylamine; Antidepressive Agents; Antiemetics; Depression; Drug Interactions; Female; Humans; | 1996 |
5-HT3 receptor antagonists reverse helpless behaviour in rats.
Topics: Analysis of Variance; Animals; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Het | 1992 |